<DOC>
	<DOCNO>NCT01642602</DOCNO>
	<brief_summary>The purpose study assess safety effectiveness daily oral administration dexlansoprazole delayed-release capsule adolescent participant symptomatic non-erosive gastroesophageal reflux disease ( GERD ) .</brief_summary>
	<brief_title>Safety Efficacy Dexlansoprazole Delayed-Release Capsules Treating Symptomatic Non-Erosive Gastroesophageal Reflux Disease Adolescents</brief_title>
	<detailed_description />
	<mesh_term>Gastroesophageal Reflux</mesh_term>
	<mesh_term>Dexlansoprazole</mesh_term>
	<mesh_term>Lansoprazole</mesh_term>
	<criteria>1 . In opinion investigator , participant parent ( ) legal guardian capable understand comply protocol requirement . 2 . Prior studyspecific procedure perform , informed consent assent form , accord local country requirement , must sign dated parent ( ) legal guardian participant , respectively . 3 . The participant medical history symptom GERD least 3 month prior Screening ( sign inform consent assent applicable ) , assess investigator . 4 . The participant meet electronic diary qualification criterion assess electronic daily diary define follow : heartburn ( burn hurt throat , chest , stomach ) least 3 7 day . 5 . The participant nonerosive GERD evidence definite endoscopic esophageal mucosal break describe Los Angeles Classification Esophagitis screen endoscopy 6 . The participant male female age 12 17 year , inclusive . 7 . A male participant nonsterilized sexually active female partner childbearing potential agrees use adequate contraception signing informed consent assent throughout duration study 30 day last dose study medication . 8 . A female participant childbearing potential may become sexually active agrees routinely use adequate contraception time sign informed consent assent 30 day last dose study medication . 1 . Participant evidence cardiovascular , pulmonary , central nervous system , hepatic , hematopoietic , renal , metabolic , endocrine gastrointestinal disease , serious allergy , asthma , allergic skin rash suggest clinically significant , uncontrolled underlying disease condition ( disease study ) , may impact ability participant participate potentially confound study result . 2 . The participant coexisting disease affect esophagus ) , ( eg , esophageal varix , scleroderma , viral fungal infection , esophageal stricture ) , history radiation therapy cryotherapy esophagus , caustic physiochemical trauma sclerotherapy esophagus . 3 . The participant known history Barrett 's dysplastic change esophagus . 4 . The participant known history eosinophilic esophagitis ( EoE ) endoscopic finding suggestive EoE . 5 . The participant history celiac disease participant test positive tTG antibody . 6 . The participant active gastric duodenal ulcer within 4 week prior Day 1 . 7 . Participant find his/her medical history , physical examination , safety clinical laboratory test give reasonable suspicion underlie disease might interfere conduct trial . 8 . Participant take PPI within 1 week ( 7 day ) prior Screening Visit . 9 . The participant history hypersensitivity allergy dexlansoprazole component dexlansoprazole PPI ( include lansoprazole , omeprazole , rabeprazole , pantoprazole , esomeprazole antacid contain Mg ( OH ) 2 / Al ( OH ) 3 simethicone . 10 . The participant require take excluded medication anticipate participant require treatment least one disallow concomitant medication study evaluation period specify Excluded Medications Treatments Section 7.3 . 11 . The participant history malignant disease ( except basal cell carcinoma ) within 5 year prior Screening . 12 . The participant condition may require inpatient surgery course study . 13 . The participant require dilatation esophageal stricture and/or stricture prevent passage endoscope Screening endoscopy . Schatzki 's ring ( ring mucosal tissue near low esophageal sphincter ) acceptable . 14 . The participant know positive human immunodeficiency virus ( HIV ) . 15 . The participant current clinical history ZollingerEllison syndrome hypersecretory condition . 16 . The participant history gastric , duodenal esophageal surgery except simple oversew ulcer . A history gastric tube and/or percutaneous endoscopic gastrostomy ( PEG ) placement allow . 17 . The participant acute upper gastrointestinal hemorrhage within 4 week prior endoscopy . 18 . The participant donate lose ≥300 mL blood volume , undergone plasmapheresis , transfusion blood product within 90 day prior first dose study drug . 19 . The participant known history alcohol abuse illegal drug use within past 12 month prior first dose study drug . 20 . The participant Screening Visit 1 abnormal laboratory value suggest clinically significant underlying disease condition may prevent participant enter study ; participant : creatinine &gt; 1.5 mg/dL , alanine aminotransferase ( ALT ) and/or aspartate aminotransferase ( AST ) &gt; 2 time upper limit normal ( ×ULN ) , total bilirubin &gt; 2.0 mg/dL AST/ALT elevate limit normal value . 21 . If female , participant pregnant lactate intend become pregnant , within 30 day last dose study medication ; intend donate ova time period . 22 . If male , participant intend donate sperm course study within 30 day last dose study drug . 23 . The participant , participant 's Parent ( ) Legal Guardian immediate family member , study site employee , dependent relationship study site employee involve conduct study may consent assent duress . Students institution/research facility supervision , subordinate role , investigator also ineligible . 24 . The participant participant 's Parent ( ) Legal Guardian , opinion investigator , unlikely comply protocol requirement unsuitable reason . 25 . The participant participate another clinical study and/or receive investigational compound within 30 day prior Screening .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Drug Therapy</keyword>
</DOC>